Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from the prospective 12-month phase of Lanro-Study
| Autor: | Krzysztof Błaut, Anna Babińska, Olga Juraniec, Sławomir Pynka, Agnieszka Stefańska, Piotr Zdunowski, Janusz Strzelczyk, Elzbieta Andrysiak-Mamos, Ewelina Lewkowicz, Beata Matyjaszek-Matuszek, Violetta Rosiek, Joanna Waligórska-Stachura, Marek Ruchała, Beata Kos-Kudła, Agata Bałdys-Waligórska, Krzysztof Sworczak, Anna Zemczak, Krzysztof Michałek, Renata Orłowska-Florek, Anna Lewczuk, Danuta Zalewska-Rydzkowska, Malgorzata Trofimiuk-Muldner, Elżbieta Bandurska-Stankiewicz, Danuta Jakubczyk, Anhelli Syrenicz, Paweł Bolko, Joanna Rutkowska, Aleksandra Jawiarczyk-Przybyłowska, Marta Peszel-Barlik, Wojciech Zgliczyński, Przemysław Witek, Jerzy Sowiński, Julia Słyńko-Krzyżostaniak, Wanda Foltyn, Ryszard Waśko, Ewa Orlewska, Roman Junik, Sławomir Mucha |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pediatrics
medicine.medical_specialty education.field_of_study Original Paper business.industry Lanreotide Autogel Population Dosing regimen clinical study Lanreotide medicine.disease Physician visit chemistry.chemical_compound Pharmacotherapy Oncology chemistry Acromegaly medicine acromegaly Radiology Nuclear Medicine and imaging Observational study lanreotide business education costs of treatment |
| Zdroj: | Contemporary Oncology |
| ISSN: | 1428-2526 |
| Popis: | AIM OF THE STUDY To assess resource utilization and costs of treatment with lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly care in Poland. MATERIAL AND METHODS A multicentre, non-interventional, observational study on resource utilization in Polish acromegalic patients treated with ATG120 at 4 weeks or extended (> 4 weeks) dosing interval. The study recruited adult acromegalic patients treated medically for ≥ 1 year including at least 3 injections of ATG120. Data on dosing interval, aspects of administration, and resource utilization were collected prospectively during 12 months. Costs were calculated in PLN from the public health-care payer perspective for the year 2013. RESULTS 139 patients were included in the analysis. Changes in dosing regimen were reported in 14 (9.4%) patients. Combined treatment was used in 11 (8%) patients. Seventy patients (50%) received ATG120 at an extended dosing interval; the mean number of days between injections was 35.56 (SD 8.4). ATG120 was predominantly administered in an out-patient setting (77%), by health-care professionals (94%). Mean time needed for preparation and administration was 4.33 and 1.58 min, respectively, mean product wastage - 0.13 mg. Patients were predominantly treated in an out-patient setting with 7.06 physician visits/patient/year. The most common control examinations were magnetic resonance imaging of brain and brain stem (1.36/patient/year), ultrasound of the neck (1.35/patient/year), GH (1.69/patient/year), glycaemia (1.12/patient/year), IGF-1 (0.84/patient/year), pituitary-thyroid axis hormone levels assessment (TSH-0.58/patient/year, T4-0.78/patient/year). There were 0.43 hospitalizations/patient/year. For direct medical costs estimated at PLN 50 692/patient/year the main item was the costs of ATG120 (PLN 4103.87/patient/month; 97%). The mean medical cost, excluding pharmacotherapy, was PLN 1445/patient/year (out-patient care - 49%, hospitalization - 23%, diagnostics/laboratory tests - 28%). CONCLUSIONS These results represent the current use of ATG120 in the population of Polish acromegalic patients in a realistic clinical setting. Findings that 50% of patients could be treated with dose intervals of longer than 28 days support the potential of ATG120 to reduce the treatment burden. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|